The interface of preclinical evaluation with clinical testing of antiepileptic drugs: Role of pharmacogenomics and pharmacogenetics

Epilepsy Research

Volumn 50, Issue 1-2, 2002, Pages 41-54

  Holmes, Gregory L ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Antiepileptic drug; Epilepsy; Human genome

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATRELEUTON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CODEINE; DEBRISOQUINE; DEXTROMETHORPHAN; ENCAINIDE; FLECAINIDE; GUANOXAN; HEXOBARBITAL; LIPOXYGENASE INHIBITOR; MEPHENYTOIN; METHYLPHENOBARBITAL; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PERHEXILINE; PHENACETIN; PHENFORMIN; PHENOBARBITAL; PHENYTOIN; PRAJMALINE; PROGUANIL; PROPAFENONE; PROPRANOLOL; SPARTEINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

BIOLOGICAL MONITORING; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EPILEPSY; GENETIC POLYMORPHISM; GENETIC PROCEDURES; HUMAN; HUMAN GENOME; MEDICAL ASSESSMENT; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; SEIZURE; TARDIVE DYSKINESIA; TECHNIQUE;

ANIMALS; ANTICONVULSANTS; DRUG EVALUATION, PRECLINICAL; EPILEPSY; GENOMICS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0036342506     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00067-0     Document Type: Conference Paper

References (75)

1. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
2. Dihydropyrimidine dehydrogenase activity: Prognostic partner of 5-fluorouracil
3. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
4. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
5. Glucose-6-phosphate dehydrogenase deficiency
6. A potassium channel mutation in neonatal human epilepsy
7. Structural and mutational analysis of KCNQ2, the major gene locus for benign familial neonatal convulsions
8. Benign familial neonatal convulsions
9. Monotherapy clinical trials of new antiepileptic drugs: Design, indications, and controversies
10. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
11. Genetic models of absence epilepsy, with emphasis on the WAG/Rij strain of rats
12. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
13. The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy
14. Impact of environmental and genetic factors on codeine analgesia
15. A mechanistic approach to understanding species differences in felbamate bioactivation: Relevance to drug-induced idiosyncratic reactions
16. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
17. Adverse drug reactions: Definitions, diagnosis, and management
18. Pharmacogenomics: Translating functional genomics into rational therapeutics
19. Apolipoprotein E genotype and gender influence response to tacrine therapy
20. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
21. A new locus for autosomal dominant nocturnal frontal lobe epilepsy maps to chromosome 1
22. Molecular genetics of the debrisoquin-sparteine polymorphism
23. A novel mutation of KCNQ3 (c.925T→C) in a Japanese family with benign familial neonatal convulsions
24. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
25. B receptor activation in absence seizures of lethargic (lh/lh) mice
26. B receptors regulate absence seizures in the lethargic (lh/lh) mouse model
27. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
28. Neuronal KCNQ potassium channels: Physiology and role in disease
29. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels
30. What is significant in whole-genome linkage disequilibrium studies
31. Prospects for whole-genome linkage disequilibrium mapping of common disease genes
32. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The regression growth evaluation statin study group
33. Early identification of refractory epilepsy
34. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE
35. Initial sequencing and analysis of the human genome
36. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
37. Benign familial neonatal convulsions linked to genetic markers on chromosome 20
38. Ion channels and epilepsy
39. Genetic heterogeneity in benign familial neonatal convulsions: Identification of a new locus on chromosome 8q
40. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs
41. Pathophysiology of seizures and epilepsy in the mature and immature brain: Cells, synapses, and circuits
42. Antiepileptic drug mechanisms of action
43. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: Analysis by population pharmacokinetics
44. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
45. New antiepileptic drugs: A systematic review of their efficacy and tolerability
46. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing
47. Benign neonatal seizures
48. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2
49. Genetic susceptibility to adverse drug reactions
50. Benign neonatal convulsions (familial and non-familial)
51. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain
52. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats
53. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain
54. Anatomical and functional aspects of mu opioid receptors in epileptic WAG/Rij rats
55. Pharmacogenetics and the practice of medicine
56. Pharmacogenetics
57. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
58. Genetic variation of the human mu-opioid receptor and susceptibility to idiopathic absence epilepsy
59. Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy
60. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
61. Basic mechanisms of generalized absence seizures
62. Tiagabine
63. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
64. Genes and mutations in idiopathic epilepsy
65. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy
66. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics
67. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration
68. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
69. The sequence of the human genome
70. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel
71. Mu opiate receptor: CDNA cloning and expression
72. Counting the costs of drug-related adverse events
73. Pharmacogenetics
74. Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy
75. HIV-1 genotypic resistance patterns predict response to saquinavir- ritonavir therapy in patients in whom previous protease inhibitor therapy had failed